Chimerix, a biopharmaceutical company, has reported encouraging data from an ongoing study of intravenous (IV) brincidofovir (BCV) following single escalating doses in healthy adult subjects.
Brincidofovir is Chimerix’s lead product candidate, and is used to treat DNA viruses that affect humans, including the herpesviruses and adenoviruses.
The company said the IV administration of BCV demonstrated a favorable tolerability profile at both doses, and that there were no drug-related adverse events, or laboratory abnormalities. It also said that even the lowest dose should provide antiviral activity.
“These preliminary results build on our preclinical studies which showed that IV brincidofovir was associated with fewer GI side effects,” said M. Michelle Berrey, CEO of Chimerix.